New Technologies for Gene Targeting + Gene Correction with David Segal, PhD

David Segal, PhD, an abstract session co-chair at the ASGCT Annual Meeting, sheds light on groundbreaking advancements in gene targeting and correction. He discusses the transition of academic innovations like CRISPR from labs to industry, aiming to benefit rare disease patients. Segal highlights the growing influence of biotech in genetic therapies and the crucial challenges of effective delivery systems. The conversation also addresses the FDA's impactful approval of the first gene editing therapy, signaling exciting times ahead for genetic medicine.